Correction to: Eye (2016) 30, 270–286; doi:10.1038/eye.2015.217; published online 4 December 2015
This article was originally published under a standard License to Publish, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.
Additional information
The online version of the original article can be found at 10.1038/eye.2015.217
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Chong, V. Erratum: Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye 30, 1526 (2016). https://doi.org/10.1038/eye.2016.202
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2016.202
This article is cited by
-
Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study
Scientific Reports (2019)
-
An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study
Graefe's Archive for Clinical and Experimental Ophthalmology (2018)
